Eli Lilly to Invest $4.5 Billion in New Indiana Drug Manufacturing Facility

The state-of-the-art Medicine Foundry will boost drug research, development, and production, creating 400 jobs by late 2027.

Eli Lilly's Medicine Foundry in Lebanon, Indiana, will combine research, development, and manufacturing under one roof.
The $4.5 billion facility will focus on molecular therapies, including small molecules, biologics, and nucleic acid therapies.
Indiana is supporting the project with infrastructure improvements and economic incentives, though the total cost to taxpayers is undisclosed.
The facility will add 400 full-time jobs for highly skilled workers, including engineers, scientists, and lab technicians.
This investment brings Lilly’s total U.S. capital commitment to over $23 billion since 2020, aimed at accelerating the delivery of next-generation medicines.